|
TaiGen Biotechnology Announces Submission of New Drug Application for Nemonoxacin in Taiwan and China
2013/05/15
More»
TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin,
to Zhejiang Medicine
2012/06/25
More»
TaiGen Biotechnology obtains the worldwide rights for Nemonoxacin
2011/12/06
More»
TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization of Nemonoxacin -- a New Generation Quinolone Antibiotic
2010/10/14
More»
TaiGen Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing in Diabetic Foot Infection Met Primary Endpoints
2010/03/12
More»
TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
2009/12/07
More»
Excellent Stem Cell Mobilization and Safety Profile for TG-0054
2009/09/28
More»
TaiGen Biotechnology Secures 37 Million USD in Series C Round Financing
2009/01/20
More» |
